View:
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )/1/
Biocryst Pharmaceuticals, Inc.
--------------------------------
(Name of Issuer)
Common Stock
--------------------------------
(Title of Class of Securities)
09058V-10-3
---------------------
(CUSIP Number)
December 1,2000
-----------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|X| Rule 13d-1(b)
o Rule 13d-1(c)
o Rule 13d-1(d)
- ------------------------
/1/ The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that Section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
Schedule 13G Page 2 of 9
CUSIP No. 09058V-10-3 Biocryst Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Berger LLC ID No. 84-1507541
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |_|
(b) |_|
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Nevada
- --------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES -0-
------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 885,720
------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING -0-
------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 885,720
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
885,720
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES |_|
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.05%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
IA, CO
- --------------------------------------------------------------------------------
- ------------------------
Schedule 13G Page 3 of 9
CUSIP No. 09058V-10-3 Biocryst Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Stilwell Financial Inc. ID No. 43-1804048
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |_|
(b) |_|
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES -0-
------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY -0-
------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING -0-
------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH -0-
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
-0-
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES |X|
Excludes shares beneficially owned by Berger LLC as to which
beneficial ownership is disclaimed.
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
HC, CO
- --------------------------------------------------------------------------------
Schedule 13G Page 4 of 9
CUSIP No. 09058V-10-3 Biocryst Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Stilwell Management, Inc. ID No. 13-2750052
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |_|
(b) |_|
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES -0-
------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY -0-
------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING -0-
------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH -0-
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
-0-
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES |X|
Excludes shares beneficially owned by Berger LLC as to which
beneficial ownership is disclaimed.
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
CO
- --------------------------------------------------------------------------------
Schedule 13G Page 5 of 9
CUSIP No. 09058V-10-3 Biocryst Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
Item 1.
(a) Name of Issuer: Biocryst Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices:
2190 Parkway Lake Dr.
Birmingham, AL 35244
Item 2.
(a) Name of Person Filing:
(1) BERGER LLC
(2) STILWELL FINANCIAL INC.
(3) STILWELL MANAGEMENT, INC.
(b) Address of Principal Business Office:
(1) BERGER LLC
210 University Boulevard, Suite 900
Denver, Colorado 80206
(2) STILWELL FINANCIAL INC.
920 Main, 21st Floor
Kansas City, MO 64105
(4) STILWELL MANAGEMENT, INC.
210 University Boulevard, Suite 900
Denver, Colorado 80206
(c) Citizenship:
(1) Berger LLC: NEVADA
(2) Stilwell Financial Inc.: DELAWARE
(3) Stilwell Management, Inc.: DELAWARE
(d) Title of Class of Securities: Common Stock
(e) CUSIP Number: 09058V-10-3
Item 3. If this statement is filed pursuant to Rule 13d-1(b), or
13d-2(b), check whether the person filing is a:
(a) ________ Broker or Dealer registered under Section 15 of the
Act
Schedule 13G Page 6 of 9
CUSIP No. 09058V-10-3 Biocryst Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(b) ________ Bank as defined in section 3(a)(6) of the Act
(c) ________ Insurance Company as defined in section 3(a)(19) of
the Act
(d) Investment Company registered under section 8 of the
-------- Investment Company Act.
(e) X Investment Adviser registered under section 203 of
-------- the Investment Advisers Act of 1940 /2/
(f) ________ Employee Benefit Plan, Pension Fund which is subject
to the provisions of the Employee Retirement Income
Security Act of 1974 or Endowment Fund; see section
240.13d-1(b)(1)(ii)(F)
(g) X Parent Holding Company, in accordance with
-------- section 240.13d-1(b)(1)(ii)(G)
(Note: See Item 7) /3/
(h) ________ A savings association as defined in Section 3(b) of
the Federal Deposit Insurance Act (12 U.S.C. 1813).
(i) ________ A church plan that is excluded from the definition
of an investment company under Section 3(c)(14) of
the Investment Company Act of 1940(15 U.S.C. 80a-3).
(j) ________ Group, in accordance with
section 240.13d-1(b)(1)(ii)(H)
Item 4. Ownership
(a) Amount Beneficially Owned:
(1) Berger LLC: 885,720 /4/
-------
(2) Stilwell Financial Inc.: 0/5/
------
(3) Stilwell Management, Inc.: 0/6/
------
(b) Percent of Class:
(1) Berger LLC: 5.05% /7/
--------
(2) Stilwell Financial Inc.: 0.00% /8/
--------
(3) Stilwell Management, Inc.: 0.00% /9/
--------
- ------------------------
/2/ Berger LLC is a registered investment adviser.
/3/ Stilwell Financial Inc. ("SFI") owns 100% of Stilwell Management, Inc.
("SMI"), which owns approximately 86% of Berger LLC. Each of these
entities is filing this statement solely as a result of such stock
ownership which may be deemed to give SFI or SMI control over Berger LLC.
/4/ The filing of this statement shall not be construed as an admission that
Berger LLC is, for purposes of Sections 13(d) or 13(g) of the Securities
Exchange Act of 1934, the beneficial owner of any securities covered by
this statement. Berger LLC is a registered investment adviser which
furnishes investment advice to a number of mutual funds and institutional
clients. As a result of its role as investment adviser or sub-adviser
to the Funds as well as institutional clients, Berger LLC may be deemed
to be the beneficial owner of securities held by such funds or clients.
/5/ Stilwell Financial Inc. ("SFI") does not own of record any shares of
Biocryst Pharmaceuticals, Inc. Common Stock, it has not engaged in any
transaction in Biocryst Pharmaceuticals, Inc. Common Stock, and it does not
exercise any voting or investment power over shares of Biocryst
Pharmaceuticals, Inc. Common Stock. All shares reported herein have been
acquired by Berger LLC's advisory clients and SFI specifically disclaims
beneficial ownership over any shares of Biocryst Pharmaceuticals, Inc.
Common Stock.
Accordingly, the filing of this statement shall not be construed as an
admission that SFI is, for purposes of Sections 13(d) or 13(g) of the
Securities Exchange Act of 1934, the beneficial owner of any securities
covered by this statement.
/6/ Stilwell Management, Inc. ("SMI") does not own of record any shares of
Biocryst Pharmaceuticals, Inc. Common Stock, it has not engaged in any
transaction in Biocryst Pharmaceuticals, Inc. Common Stock, and it does
not exercise any voting or investment power over shares of Biocryst
Pharmaceuticals, Inc. Common Stock. All shares reported herein have been
acquired by Berger LLC's advisory clients and SMI specifically disclaims
beneficial ownership over any shares of Biocryst Pharmaceuticals, Inc.
Common Stock.
Accordingly, the filing of this statement shall not be construed as an
admission that SMI is, for purposes of Sections 13(d) or 13(g) of the
Securities Exchange Act of 1934, the beneficial owner of any securities
covered by this statement.
/7/ The filing of this statement shall not be construed as an admission that
Berger LLC is, for purposes of Sections 13(d) or 13(g) of the Securities
Exchange Act of 1934, the beneficial owner of any securities covered by
this statement.
/8/ See Item 4(a)(2).
/9/ See Item 4(a)(3).
Schedule 13G Page 7 of 9
CUSIP No. 09058V-10-3 Biocryst Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(c) Number of shares as to which such person has:
(1) Berger LLC:
(i) Sole power to vote or to direct the
vote: 0
------
(ii) Shared power to vote or to direct the
vote: 885,720
------
(iii) Sole power to dispose or to direct the
disposition of: 0
------
(iv) Shared power to dispose or to direct the
disposition of: 885,720
------
(2) Stilwell Financial Inc.
(i) Sole power to vote or to direct the
vote: 0
------
(ii) Shared power to vote or to direct the
vote: 0 /10/
------
(iii) Sole power to dispose or to direct the
disposition of: 0
------
(iv) Shared power to dispose or to direct the
disposition of: 0 /11/
------
(2) Stilwell Management, Inc.
(i) Sole power to vote or to direct the
vote: 0
------
(ii) Shared power to vote or to direct the
vote: 0 /12/
------
(iii) Sole power to dispose or to direct the
disposition of: 0
------
(iv) Shared power to dispose or to direct the
disposition of: 0 /13/
------
Item 5. Ownership of Five Percent or Less of a Class:
N/A
Item 6. Ownership of More than Five Percent on Behalf of Another
Person:
N/A
- -------------------
10 See Item 4(a)(2)
11 See Item 4(a)(2)
12 See Item 4(a)(3)
13 See Item 4(a)(3)
Schedule 13G Page 8 of 9
CUSIP No. 09058V-10-3 Biocryst Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent
Holding Company:
THIS STATEMENT HAS BEEN FILED JOINTLY BY SFI, SMI AND BERGER LLC, AND
INFORMATION RELATING TO BERGER LLC HAS BEEN INCLUDED HEREIN.
Item 8. Identification and Classification of Members of the Group:
N/A
Item 9. Notice of Dissolution of Group:
N/A
Item 10. Certification:
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired and
are held in the ordinary course of business and were not
acquired and are not held for the purpose of or with the
effect of changing or influencing the control of the issuer of
such securities and were not acquired and are not held in
connection with or as a participant in any transaction having
such purpose or effect.
Schedule 13G Page 9 of 9
CUSIP No. 09058V-10-3 Biocryst Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
BERGER LLC:
February 14, 2001
--------------------------------------------
Date
/s/ Brian S. Ferrie
--------------------------------------------
Signature
Brian S. Ferrie, Vice President - Compliance
--------------------------------------------
Name/Title
STILWELL FINANCIAL INC.
February 14, 2001
--------------------------------------------
Date
/s/ GWEN E. ROYLE
--------------------------------------------
Signature
Gwen E. Royle
Vice President-Legal and Corporate Secretary
--------------------------------------------
Name/Title
STILWELL MANAGEMENT, INC.
/S/JACK R. THOMPSON
------------------------------------
Jack R. Thompson, President and
Chief Executive Officer
EXHIBIT INDEX
Exhibit Document Page No.
- ------- -------- --------
A Joint Filing Agreement A-1
Exhibit A
to
SCHEDULE 13G
JOINT FILING AGREEMENT
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934,
the undersigned parties hereby agree that the preceding Schedule 13G is being
filed on behalf of each of them.
IN WITNESS THEREOF, the parties hereto have duly executed this
agreement on this 14th day of February, 2001.
BERGER LLC:
/S/BRIAN S. FERRIE
------------------------------------
Brian S. Ferrie, Vice President -
Compliance
STILWELL FINANCIAL INC.
/S/GWEN E. ROYLE
------------------------------------
Gwen E. Royle, Vice President - Legal
and Corporate Secretary
STILWELL MANAGEMENT, INC.
/S/JACK R. THOMPSON
------------------------------------
Jack R. Thompson, President and
Chief Executive Officer
A-1